262 related articles for article (PubMed ID: 34054800)
61. Knowledge and awareness about human papillomavirus infection and its vaccination among women in Arab communities.
Alsous MM; Ali AA; Al-Azzam SI; Abdel Jalil MH; Al-Obaidi HJ; Al-Abbadi EI; Hussain ZK; Jirjees FJ
Sci Rep; 2021 Jan; 11(1):786. PubMed ID: 33436959
[TBL] [Abstract][Full Text] [Related]
62. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
63. Human papillomavirus vaccine: widening the scope for cancer prevention.
No JH; Kim MK; Jeon YT; Kim YB; Song YS
Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
[TBL] [Abstract][Full Text] [Related]
64. Practice towards human papillomavirus vaccines among Malaysian women: a survey of a general youth population.
Al-Naggar RA; Bobryshev YV
Asian Pac J Cancer Prev; 2011; 12(8):2045-9. PubMed ID: 22292648
[TBL] [Abstract][Full Text] [Related]
65. Age considerations when vaccinating against HPV.
Wright TC; Huh WK; Monk BJ; Smith JS; Ault K; Herzog TJ
Gynecol Oncol; 2008 May; 109(2 Suppl):S40-7. PubMed ID: 18482558
[TBL] [Abstract][Full Text] [Related]
66. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
67. HPV vaccination: The most pragmatic cervical cancer primary prevention strategy.
Sankaranarayanan R
Int J Gynaecol Obstet; 2015 Oct; 131 Suppl 1():S33-5. PubMed ID: 26433502
[TBL] [Abstract][Full Text] [Related]
68. The last strategy for re-dissemination of HPV vaccination in Japan while still under the suspension of the governmental recommendation.
Ueda Y; Yagi A; Abe H; Nakagawa S; Minekawa R; Kuroki H; Miwa A; Kimura T
Sci Rep; 2020 Sep; 10(1):16091. PubMed ID: 32999408
[TBL] [Abstract][Full Text] [Related]
69. Cost-utility analysis of vaccination against HPV in Israel.
Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J
Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844
[TBL] [Abstract][Full Text] [Related]
70. Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005.
Dunne EF; Flagg EW; Unger ER; Hsu K; Ghanen K; Kerndt P; Shlay JC; Koutsky LA; Datta DS; Panicker G; Zaidi A; Weinstock H; Markowitz LE
Sex Transm Dis; 2014 Jan; 41(1):46-9. PubMed ID: 24326582
[TBL] [Abstract][Full Text] [Related]
71. Factors associated with human papillomavirus vaccination among young adult women in the United States.
Williams WW; Lu PJ; Saraiya M; Yankey D; Dorell C; Rodriguez JL; Kepka D; Markowitz LE
Vaccine; 2013 Jun; 31(28):2937-46. PubMed ID: 23643629
[TBL] [Abstract][Full Text] [Related]
72. HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US.
Liu G; Kong L; Du P
Papillomavirus Res; 2016 Dec; 2():1-8. PubMed ID: 26623444
[TBL] [Abstract][Full Text] [Related]
73. Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs.
Markowitz LE; Drolet M; Lewis RM; Lemieux-Mellouki P; Pérez N; Jit M; Brotherton JM; Ogilvie G; Kreimer AR; Brisson M
Vaccine; 2022 Sep; 40(37):5413-5432. PubMed ID: 35965239
[TBL] [Abstract][Full Text] [Related]
74. Elimination of cervical cancer depends on HPV vaccination and primary HPV screening.
Harper DM; Jimbo M
Lancet Infect Dis; 2021 Oct; 21(10):1342-1344. PubMed ID: 34081924
[No Abstract] [Full Text] [Related]
75. Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics.
Tiro JA; Pruitt SL; Bruce CM; Persaud D; Lau M; Vernon SW; Morrow J; Skinner CS
Vaccine; 2012 Mar; 30(13):2368-75. PubMed ID: 22108490
[TBL] [Abstract][Full Text] [Related]
76. Immunogenicity of 2-Dose HPV Vaccine Series for Postpartum Women: An Open-Label, Nonrandomized, Noninferiority Trial.
Moss CF; Wang R; Sao S; Chou B; Perin J; Lander ME; Thaker SM; Mann M; Coleman JS
JAMA Netw Open; 2024 Jan; 7(1):e2352996. PubMed ID: 38285445
[TBL] [Abstract][Full Text] [Related]
77. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer.
Kjaer SK; Dehlendorff C; Belmonte F; Baandrup L
J Natl Cancer Inst; 2021 Oct; 113(10):1329-1335. PubMed ID: 33876216
[TBL] [Abstract][Full Text] [Related]
78. Assessing the need for and acceptability of a free-of-charge postpartum HPV vaccination program.
Berenson AB; Male E; Lee TG; Barrett A; Sarpong KO; Rupp RE; Rahman M
Am J Obstet Gynecol; 2014 Mar; 210(3):213.e1-7. PubMed ID: 24280248
[TBL] [Abstract][Full Text] [Related]
79. Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial.
Tsang SH; Sampson JN; Schussler J; Porras C; Wagner S; Boland J; Cortes B; Lowy DR; Schiller JT; Schiffman M; Kemp TJ; Rodriguez AC; Quint W; Gail MH; Pinto LA; Gonzalez P; Hildesheim A; Kreimer AR; Herrero R;
J Natl Cancer Inst; 2020 Oct; 112(10):1030-1037. PubMed ID: 32091596
[TBL] [Abstract][Full Text] [Related]
80. Using financial incentives to increase initial uptake and completion of HPV vaccinations: protocol for a randomised controlled trial.
Mantzari E; Vogt F; Marteau TM
BMC Health Serv Res; 2012 Sep; 12():301. PubMed ID: 22947332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
